Spotlight on Ivermectin

Mechanisms of Action

• Signaling Pathway Inhibition: Blocks Wnt, Notch, Hedgehog, NFκB, STAT3, and PI3K/Akt pathways, limiting CSC renewal, proliferation, and metastasis.
• Inhibition of Cancer Stem Cells: Selectively cytotoxic to CSC-rich populations, downregulates genes essential for “stemness” (Nanog, Oct-4, Sox-2) in breast cancer models.
• Mitochondrial Disruption: Induces mitochondrial dysfunction, leading to oxidative stress and apoptosis in multiple cancer types.
• Immunomodulation: Converts immunologically “cold” tumors into “hot” by enhancing T-cell infiltration and immunotherapy responsiveness (notable in gliomas).
• Synergy with Chemotherapy/Immunotherapy: Enhances standard chemotherapy efficacy and works synergistically with metabolic agents and checkpoint inhibitors.

Clinical Evidence

• Broad-Spectrum Activity: Demonstrated efficacy in preclinical models of breast (including triple-negative), bladder, lung, glioma, multiple myeloma, ovarian, pancreatic, colon, melanoma, and others.
• Recent Trials: Ongoing Phase I/II studies explore ivermectin in combination with immunotherapy (balstilimab) for metastatic triple negative breast cancer; over 150 case reports in diverse cancer settings (ASCO 2025).
• Synergistic Protocols: Used combinatorially with fenbendazole, curcumin, vitamin D, and other orthomolecular agents; notable in metastatic and resistant cases.
• Safety: Well-tolerated at recommended doses; adverse effects (GI symptoms, dizziness) are generally mild; higher doses require monitoring for hepatic or neurological toxicity.

Dosing and Protocols

• Functional Medicine Protocols: Common dosing 0.2–1.0 mg/kg/day (tailored to disease and patient tolerance); included in both limited and aggressive functional oncology protocols.
• Adjunctive Role: Combined with lifestyle changes, immune support, and targeted supplements; dose adjustments and monitoring per individual case.

Clinical Considerations

Ivermectin’s ability to cross relevant biological barriers (e.g., blood-brain barrier), target CSCs, and modulate immunity suits the functional and integrative model—particularly in patients who have exhausted standard options or require low-toxicity adjuncts.

References & Published Protocols

• Molecular Medicine Reports 2017 (CSC inhibition)
• Internal Healing & Wellness MD December 2024 [protocol]
• Cancers 2025 (Review)
• ASCO 2025 Abstract e13146 (trial)
• FLCCC/IMA protocols (Marik, Hope)

---

For Healthcare Professionals

These materials are for informational and educational use in professional settings. Prescribers are encouraged to review primary literature and consult experienced integrative/functional medicine colleagues prior to initiating therapy. All compounds described remain investigational or off-label for oncologic indications and should be prescribed with patient consent, appropriate monitoring, and as part of a holistic, patient-centered plan.

Brand, Availability & Personalized Compounding

Skip’s Pharmacy stands ready to support your clinic in the safe, evidence-based use of repurposed medications for cancer and chronic disease care.

Empowering Practitioners. Advancing Integrative Cancer Care.

Contact Skip’s Pharmacy to learn more about optimized, protocol-backed access to these therapies for your patients today.

This is for professional informational purposes only. Not intended as patient medical advice. All therapies should be supervised by a qualified healthcare provider.